Skip to main content
SpringerLink
Log in

Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents

A Comparative Review

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

The current approach to antimigraine therapy comprises potent serotonin 5-HT1B/1D receptor agonists collectively termed triptans. Sumatriptan was the first of these compounds to be developed, and offered improved efficacy and tolerability over ergot-derived compounds. The development of Sumatriptan was quickly followed by a number of ‘second generation’ triptan compounds, characterised by improved pharmacokinetic properties and/or tolerability profiles. Triptans are believed to effect migraine relief by binding to serotonin (5-hydroxy-tryptamine) receptors in the brain, where they act to induce vasoconstriction of extracerebral blood vessels and also reduce neurogenic inflammation.

Although the pharmacological mechanism of the triptans is similar, their pharmacokinetic properties are distinct. For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan). Clearly, such diverse pharmacokinetic properties will influence the effectiveness of the compounds and favour the prescription of one over another in different patient populations. This article reviews the pharmacological properties of the triptans (time to peak plasma concentration, half-life, bioavailability and receptor binding) and relates these properties to efficacy and time of onset. It also considers the effects of concomitant medication, food, age and disease on the pharmacokinetics of the compounds. In addition, the relative merits, such as headache recurrence, tolerability and route of administration, are discussed. Finally, the performance of the triptans is considered in the context of direct head-to-head comparative trials that have assessed the efficacy profile of the compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Meyer JS, Zetusky W, Jonsdottir M, et al. Cephalic hyperemia during migraine headaches: a prospective study. Headache 1986; 26: 388–97

    Article  PubMed  CAS  Google Scholar 

  2. Weitzel KW, Thomas ML, Small RE, et al. Migraine: a comprehensive review of new treatment options. Pharmacotherapy 1999; 19: 957–73

    Article  PubMed  CAS  Google Scholar 

  3. Silberstein SD. Serotonin (5-HT) and migraine. Headache 1994; 34: 408–17

    Article  PubMed  CAS  Google Scholar 

  4. Humphrey P, Feniuk W. Mode of action of the antimigraine drug Sumatriptan. Trends Pharmacol Sci 1991; 12: 444–6

    Article  PubMed  CAS  Google Scholar 

  5. Rebeck GW, Maynard KI, Hyman BT, et al. Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci U S A 1994; 91: 3666–9

    Article  PubMed  CAS  Google Scholar 

  6. Goadsby PJ. Studies of cerebrovascular pain pathways of relevance to migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models. Philadelphia (PA): Lippincott Raven Press, 1995: 5–25

    Google Scholar 

  7. Goadsby PH, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT) 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355–9

    Article  PubMed  CAS  Google Scholar 

  8. Ferrari MD. Rizatriptan: a new milestone in migraine treatment. Headache 1999; 39 Suppl. 1: S1

    Article  Google Scholar 

  9. Goadsby PJ. Understanding migraine pathophysiology through studying the mechanism of action of rizatriptan. Headache 1999; 39 Suppl. 1: S2–8

    Article  Google Scholar 

  10. Meijler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5–10

    Article  Google Scholar 

  11. Oral Sumatriptan Dose-defining Study Group. Sumatriptan — an oral dose-defining study. Eur Neurol 1991; 31: 300–5

    Article  Google Scholar 

  12. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous Sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361–5

    Article  PubMed  CAS  Google Scholar 

  13. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of Sumatriptan. Eur Neurol 1991; 31: 291–4

    Article  PubMed  CAS  Google Scholar 

  14. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of Sumatriptan in human liver. Biochem Pharmacol 1994; 47: 1253–7

    Article  PubMed  CAS  Google Scholar 

  15. Blier P, Bergeron R. The safety of concomitant use of Sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995; 15: 106–9

    Article  PubMed  CAS  Google Scholar 

  16. Mathew NT, Kailasam L, Gentry P, et al. Treatment of oral Sumatriptan nonresponders with 5 mg zolmitriptan and 10 mg rizatriptan: a comparative open trial. Headache 1999; 39: 368

    Google Scholar 

  17. Salonen R, Ashford EA, Biggs M, et al. Patient preference for oral Sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Int J Clin Pract Suppl 1999; 105: 16–24

    PubMed  CAS  Google Scholar 

  18. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal Sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 532–8

    Article  PubMed  CAS  Google Scholar 

  19. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of Sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543–8

    Article  PubMed  CAS  Google Scholar 

  20. Scott R, Aitchison W, Barker P, et al. Oral Sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. Q J Med 1996; 89: 613–22

    Article  CAS  Google Scholar 

  21. Cull RE, Price WH, Dunbar A. The efficacy of subcutaneous Sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychiatry 1997; 62: 490–5

    Article  PubMed  CAS  Google Scholar 

  22. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with Sumatriptan. N Engl J Med 1991; 325:316–21

    Article  Google Scholar 

  23. The Oral Sumatriptan International Multiple Dose Study Group. Evaluation of a multiple dose regiment of oral Sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306–13

    Article  Google Scholar 

  24. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral Sumatriptan in acute migraine. Lancet 1991; 338: 782–3

    Article  PubMed  CAS  Google Scholar 

  25. Ferrari MD, Saxena PR. Clinical and experimental effects of Sumatriptan in humans. Trends Pharmacol Sci 1993; 14: 129–33

    Article  PubMed  CAS  Google Scholar 

  26. Dahlof C. Headache recurrence after subcutaneous Sumatriptan and early treatment. Lancet 1992; 340: 909

    Article  PubMed  CAS  Google Scholar 

  27. Rapoport AM, Visser WH, Cutler NR, et al. Oral Sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous Sumatriptan. Neurology 1995; 45: 1505–9

    Article  PubMed  CAS  Google Scholar 

  28. Dahlöf C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999; 19: 769–8

    Article  PubMed  Google Scholar 

  29. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225–30

    Article  PubMed  CAS  Google Scholar 

  30. Van der Bijl P, Penkler L, van Eyk AD. Permeation of Sumatriptan through human vaginal and buccal mucosa. Headache 2000; 40: 137–41

    Article  PubMed  Google Scholar 

  31. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of Sumatriptan in human liver. Biochem Pharmacol 1994; 47: 1254–7

    Article  Google Scholar 

  32. Drug facts and comparison. St Louis (MO): Facts and Comparisons, 2000: 849-56

  33. Williams P, Fuseau E, Cosson V, et al. Sumatriptan pharmacokinetics are significantly altered by monoamine oxidase inhibitor co-administration. Cephalalgia 1997; 3: 408

    Google Scholar 

  34. Physician’s desk reference. Montvale (NJ): Medical Economics Inc., 2000: 587-590, 1148-51, 1195-208, 1822-6

  35. Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 337–44

    Article  PubMed  CAS  Google Scholar 

  36. Dahlöf CGH, Mathew N. Cardiovascular safety of 5HT1B/1D agonists — Is there a cause for concern? Cephalalgia 1998; 18: 539–45

    Article  PubMed  Google Scholar 

  37. Visser WH, Jaspers NM, de Vriend RH, et al. Chest symptoms after Sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996: 16: 554–9

    Article  PubMed  CAS  Google Scholar 

  38. Dahlöf CG. How does Sumatriptan perform in clinical practice? Cephalalgia 1995; 15: 21–8

    PubMed  Google Scholar 

  39. Wilkinson M, Pfaffenrath V, Schoenen J, et al. Migraine and cluster headache: their management with Sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995; 15: 337–57

    PubMed  CAS  Google Scholar 

  40. Putnam GP, O’Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of Sumatriptan: a largescale, prospective study. Cephalalgia 1999; 19: 668–75

    Article  PubMed  CAS  Google Scholar 

  41. Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between Sumatriptan and naproxen. J Clin Pharmacol 2000; 40: 99–104

    Article  PubMed  CAS  Google Scholar 

  42. Srinivas NR, Shyu WC, Upmalis D, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and Sumatriptan succinate. J Clin Pharmacol 1995; 35: 432–7

    PubMed  CAS  Google Scholar 

  43. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between Propranolol and Sumatriptan. Br J Clin Pharmacol 1991;32:581–4

    Article  PubMed  CAS  Google Scholar 

  44. Gardner DM, Lynd LD. Sumatriptan contraindications and serotonin syndrome. Ann Pharmacother 1998; 32: 33–8

    Article  PubMed  CAS  Google Scholar 

  45. Wojnar-Horton RE, Hackett LP, Yapp P, et al. Distribution and excretion of Sumatriptan in human milk. Br J Clin Pharmacol 1996;41:217–21

    Article  PubMed  CAS  Google Scholar 

  46. Goadsby PJ. Emerging oral triptan therapies. Headache 1999; 39 Suppl. 2: S40–8

    Article  Google Scholar 

  47. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994; 34: 394–9

    Article  PubMed  CAS  Google Scholar 

  48. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997; 43: 579–87

    Article  PubMed  CAS  Google Scholar 

  49. Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl. 18: 15–20

    PubMed  Google Scholar 

  50. Martin GR, Dixon R. Pre-clinical and clinical pharmacology of the novel anti-migraine compound 311C90. Headache 1995; 53: 291

    Google Scholar 

  51. Dixon R, French S, Kemp J, et al. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J Clin Pharmacol 1998; 38: 694–701

    PubMed  CAS  Google Scholar 

  52. Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999; 29: 847–57

    Article  PubMed  CAS  Google Scholar 

  53. Gillotin C, Bagnis C, Mamet JP, et al. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Int J Clin Pharmacol Ther 1997; 35: 522–6

    PubMed  CAS  Google Scholar 

  54. Seaber EJ, Peck RS, Smith DA, et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1998; 46: 433–9

    Article  PubMed  CAS  Google Scholar 

  55. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 1998; 63: 342–53

    Article  PubMed  CAS  Google Scholar 

  56. Dixon R, Gillotin C, Gibbens M, et al. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273–81

    Article  PubMed  CAS  Google Scholar 

  57. Lance JW, Goadsby PJ. Mechanism and management of headache. 6th ed. London: Butterworth-Heinemann, 1998

    Google Scholar 

  58. Smith DA, Cleary EW, Watkins S, et al. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J Clin Pharmacol 1998; 38: 685–93

    PubMed  CAS  Google Scholar 

  59. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zornig, 311C90). Cephalalgia 1997; 17 Suppl. 18: 21–7

    PubMed  Google Scholar 

  60. Peck RW, Seaber EJ, Dixon R, et al. The interaction between Propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol 1997; 44: 595–9

    Article  PubMed  CAS  Google Scholar 

  61. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebocontrolled, dose range-finding study. Neurology 1997; 49: 1210–8

    Article  PubMed  CAS  Google Scholar 

  62. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–25

    Article  PubMed  CAS  Google Scholar 

  63. Fuseau E, Baille P, Kempsford RD. A study to determine the absolute bioavailability of naratriptan [abstract]. Cephalalgia 1997; 17: 417

    Google Scholar 

  64. Kempsford RD, Baille P, Fuseau E. Oral naratriptan tablets (2.5-10 mg) exhibit dose-proportional pharmacokinetics [abstract]. Cephalalgia 1997; 17: 408

    Google Scholar 

  65. Fuseau E, Webster C, Asgharnejad M, et al. Naratriptan oral pharmacokinetics in migraine subjects [abstract]. J Neurol Sci 1997; 150 (Suppl.): S168

    Google Scholar 

  66. Dahlof C, Hogenhuis L, Olesen J, et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur JNeurol 1998; 5: 469–77

    Article  Google Scholar 

  67. Connor H, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17: 145–52

    Article  PubMed  CAS  Google Scholar 

  68. Dulli CA. Naratriptan: an alternative for migraine. Ann Pharmacother 1999; 33: 704–11

    Article  PubMed  CAS  Google Scholar 

  69. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49: 1485–90

    Article  PubMed  CAS  Google Scholar 

  70. Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 1997; 37: 640–5

    Article  PubMed  CAS  Google Scholar 

  71. Yogendran L, Boswell D, Nacci P, et al. Effect of subcutaneous naratriptan on forearm blood flow. Cephalalgia 1998; 18: 476–80

    Article  PubMed  CAS  Google Scholar 

  72. Hood S, Birnie D, Swan L, et al. Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. J Cardiovasc Pharmacol 1999; 34(1): 89–94

    Article  PubMed  CAS  Google Scholar 

  73. Bomhof MA, Heywood J, Pradalier A, et al. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group. Cephalalgia 1998; 18: 33–7

    Article  PubMed  CAS  Google Scholar 

  74. Sheftell F, O’Quinn S, Watson C, et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000; 40: 103–10

    Article  PubMed  CAS  Google Scholar 

  75. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of Sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral Sumatriptan. Headache 1998; 38: 184–90

    Article  PubMed  CAS  Google Scholar 

  76. Beer M, Meddlemiss D, Stanton J, et al. In vitro pharmacological profile of the novel 5-HT1D receptor agonist MK-462. Cephalalgia 1995; 15 Suppl. 14: 203

    Google Scholar 

  77. Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos 2000; 28: 89–95

    PubMed  CAS  Google Scholar 

  78. Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999; 47: 373–8

    Article  PubMed  CAS  Google Scholar 

  79. Cutler NR, Jhee SS, Majumdar AK, et al. Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache 1999; 39: 264–9

    Article  PubMed  CAS  Google Scholar 

  80. Cheng H, Polvino WJ, Sciberras D, et al. Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996; 17: 12–24

    CAS  Google Scholar 

  81. van Haarst AD, van Gervan JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1Dagonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48: 190–6

    Article  PubMed  Google Scholar 

  82. Lipton RB. Pharmacologic profile and clinical efficacy of rizatriptan. Headache 1999; 39 Suppl. 1: S9–15

    Article  Google Scholar 

  83. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998; 38: 281–7

    Article  PubMed  CAS  Google Scholar 

  84. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773–81

    Article  PubMed  CAS  Google Scholar 

  85. Gerth WC, Mannix LK, McCarroll KA, et al. Patient satisfaction with rizatriptan 10 mg vs other triptans: head-to-head comparisons. Headache 2000; 40: 408–9

    Google Scholar 

  86. Ferrari MD, Lipton RB, McCarroll KA, et al. 24-hour sustained pain free status after rizatriptan and other triptans: a comparison. Headache 2000; 40: 407–8

    Google Scholar 

  87. Napier C, Stewart M, Melrose H, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999; 368: 259–68

    Article  PubMed  CAS  Google Scholar 

  88. McHarg AD, Napier CM, Stewart M, et al. The functional activity of eletriptan and other 5-HT1B/1Dagonists at the human recombinant 5-HT1B and 5-HTID receptors. Headache 1999; 39: 369

    Google Scholar 

  89. Shah A, Johnson BF, Groton CT, et al. The pharmacokinetics of eletriptan - a new oral agent for the acute treatment of migraine. Neurology 1998; 50: A377

    Google Scholar 

  90. Milton KA, Allen MJ, Abel S, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective ‘5HT1D-like’ receptor partial agonist. Cephalalgia 1997; 17: 44

    Google Scholar 

  91. Rhodes K. IDDB Meeting report. XIth Migraine Trust International Symposium; 1996 Sep 9–12; London

    Google Scholar 

  92. Hyland R, Jones BC, McCleverty P, et al. In vitro metabolism of eletriptan in human liver microsomes. Cephalalgia 1998; 18: 404

    Google Scholar 

  93. Meng CQ. Eltriptan. Curr Opin CPNS Invest Drugs 2000; 2: 186–96

    CAS  Google Scholar 

  94. Diener HC. Eletriptan and coronary artery. Clin Pharmacol Ther 2000; 67: 326

    PubMed  CAS  Google Scholar 

  95. Poole PH. Measures of rapid resolution of migraine symptoms and patient acceptance to treatment following eletriptan, Sumatriptan and placebo [abstract]. Neurology 1998; 50: A375

    Google Scholar 

  96. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to Sumatriptan. Neurology 2000; 54: 156–63

    Article  PubMed  CAS  Google Scholar 

  97. Eletriptan approved amid dose concerns. Scrip 2000 Sep 15; 2575: 22

  98. MacGregor EA. Migraine during menstruation and the efficacy of oral eletriptan. Neurology 1998; 50: A377

    Google Scholar 

  99. Pitei D, Hettiarachchi J. Efficacy of eletriptan in treating women with menstrually associated migraine and women on oral contraceptives or hormone replacement therapy. Obstet Gynecol 2000; 95(4) Suppl. 1: S32

    Article  Google Scholar 

  100. Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia 1999; 19: 16–9

    Article  PubMed  CAS  Google Scholar 

  101. Newman LC, Mannix LK, Silberstein SD, et al. Naratriptan as prophylaxis for menstrually-associated migraine: a randomized, double blind, placebo-controlled study. Headache 2000; 40: 422

    Google Scholar 

  102. Bou J, Domenech T, Gras J, et al. Pharmacological profile of almotriptan, a novel antimigraine agent. Cephalalgia 1997; 19: 421–2

    Google Scholar 

  103. Bou J, Cardelus I, Llenas J, et al. Antimigraine potential of almotriptan in animal models. Methods Find Exp Clin Pharmacol 1997; 19 (Suppl.): A107

    Google Scholar 

  104. Cabarrocas X, Zayas JM, Suris M. Equivalent efficacy of oral almotriptan, a new 5-HT11B/1D agonist, compared with Sumatriptan 100 mg. Headache 1998; 38: 377

    Google Scholar 

  105. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. Oral almotriptan vs oral Sumatriptan in a double-blind, randomized, parallel-group study in migraine patients. Headache 2000; 40: 433

    Google Scholar 

  106. Fernandez FJ, Jansat JM, Cabarrocas X, et al. Absolute bioavailability of oral and subcutaneous almotriptan. Cephalalgia 1999; 19: 363

    Google Scholar 

  107. Robert M, Warrington SJ, Zayas JM, et al. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalalgia 1998; 18: 406

    Google Scholar 

  108. Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between Verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67: 498–503

    Article  PubMed  CAS  Google Scholar 

  109. Cabarrocas X, Warrington SJ, Jansat JM, et al. Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia 1999; 19: 363

    Google Scholar 

  110. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997; 17: 421

    Google Scholar 

  111. Salva M, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans. Issx Meet Rep 1997; 30(6): 174

    Google Scholar 

  112. Kamali F. Almotriptan. Curr Opin CPNS Invest Drugs 2000; 2: 197–202

    CAS  Google Scholar 

  113. Martinez E, Cabarrocas X, Peris F, et al. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 1999; 19: 362

    Google Scholar 

  114. Robert M, Cabarrocas X, Zayas JM, et al. Overall response of oral almotriptan in the treatment of three migraine attacks. Cephalalgia 1999; 19: 363

    Google Scholar 

  115. Buchan P. The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent selective 5-HT1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Headache 1998; 38: 376

    Google Scholar 

  116. Buchan P, Ward C, Stewart AJ. The effect of Propranolol on the pharmacokinetic and safety profiles of frovatriptan. Headache 1999; 39(5): 345

    Google Scholar 

  117. Buchan P, Keywood C, Ward C, et al. Pharmacokinetics of frovatriptan in young and elderly subjects. Headache 1999; 39: 346

    Google Scholar 

  118. Buchan P, Ward C, Stewart AJ, et al. Frovatriptan has no clinically significant interactions with moclobemide, Propranolol or ergotamine. Headache 2000; 40: 402

    Google Scholar 

  119. Cohen AF, van der Post J, Sacks S, et al. Pharmacokinetics of frovatriptan in patients with renal impairment. Cephalalgia 1999; 19: 365

    Google Scholar 

  120. Buchan P, Ward C, Zeig S. Frovatriptan pharmacokinetics are unaffected during a migraine attack. Cephalalgia 1999; 19: 365

    Google Scholar 

  121. Parsons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT (IB/ID) receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998; 32: 220–4

    Article  PubMed  CAS  Google Scholar 

  122. Raval P, Tilford NS, Smith SJ, et al. Acomparison of the agonist profile of SB 208509 (VML 251) and Sumatriptan in human isolated basilar and coronary arteries. Br J Pharmacol 1996; 119 (Proc Suppl.): 111P

    Google Scholar 

  123. Elkind AH, Satin L, Keywood C. Frovatriptan cardiovascular safety in patients at high risk or with overt coronary artery disease during an acute migraine attack. Headache 2000; 40: 407

    Google Scholar 

  124. Elkind A, McDaris HL, Satin L, et al. Cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack. Cephalalgia 1999; 19: 365

    Google Scholar 

  125. Rapoport AM, Key wood C. Frovatriptan—dose response studies. Headache 1999; 39; 375

    Article  Google Scholar 

  126. Goldstein J, Elkind A, Key wood C, et al. A low-dose range-finding study of frovatriptan: a potent selective 5-HT1B/1D agonist for the acute treatment of migraine. Headache 1998; 38: 382

    Google Scholar 

  127. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral Sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748–55

    Article  PubMed  CAS  Google Scholar 

  128. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus Sumatriptan 25 mg and 50 mg in migraine. Headache 1998; 38: 737–47

    Article  PubMed  CAS  Google Scholar 

  129. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs Sumatriptan in the acute treatment of migraine: a placebocontrolled, dose-ranging study. Arch Neurol 1996; 53:1132–7

    Article  PubMed  CAS  Google Scholar 

  130. Gallagher RM, Dennish G, Spierings ELH, et al. Acomparative trial of zolmitriptan and Sumatriptan for the acute oral treatment of migraine. Headache 2000; 40: 119–28

    Article  PubMed  CAS  Google Scholar 

  131. Geraud G, Olesen J, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and Sumatriptan: issues in migraine trial design. Cephalalgia 2000; 20: 30–8

    Article  PubMed  CAS  Google Scholar 

  132. Pitman V, Forster E, Jackson NJ. Comparison of the efficacy of oral eletriptan and oral Sumatriptan for the acute treatment of migraine: combined analysis across three clinical trials. Headache 1999; 39: 374

    Google Scholar 

  133. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999; 42: 173–9

    Article  PubMed  CAS  Google Scholar 

  134. Diener HC, Pascual J, Vega P. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine. Headache 1999; 39:351

    Google Scholar 

  135. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan vs. other triptans on a composite measure of efficacy at 2 hours: freedom from pain and associated symptoms. Headache 2000; 40: 401

    Article  Google Scholar 

  136. Krusz JC, Nett RB. Naratriptan is effective in preventing recurrence of migraine headache after initial relief with Sumatriptan. Headache 2000; 40: 414

    Article  Google Scholar 

  137. Cochran JW. Concurrent use of Sumatriptan and naratriptan in migraineurs with recurrent headache. Headache 2000; 40: 404–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Clinical Trials, 8501 Wilshire Blvd, Beverly Hills, California, 90211, USA

    Stanford S. Jhee, Thomas Shiovitz, Aaron W. Crawford & Neal R. Cutler

Authors
  1. Stanford S. Jhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Shiovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aaron W. Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neal R. Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanford S. Jhee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jhee, S.S., Shiovitz, T., Crawford, A.W. et al. Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents. Clin Pharmacokinet 40, 189–205 (2001). https://doi.org/10.2165/00003088-200140030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200140030-00004

Keywords

Search

Navigation